Clinical Trial Update: Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating whether eplerenone reduces recurrence of atrial fibrillation in patients with structural heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• eplerenone (eplerenone)

Snippet

Sponsor: Assiut University | Conditions: Paroxysmal Atrial Fibrillation | Phase 4 | Status: NOT_YET_RECRUITING